Wilms tumor in childhood: Single centre retrospective study from the National Institute of Oncology of Rabat and literature review  by Rais, Fadoua et al.
at ScienceDirect
Pediatric Hematology Oncology Journal 1 (2016) 28e34Contents lists availablePediatric Hematology Oncology Journal
journal homepage: ht tps: / /www.elsevier .com/journals /pediatr ic-
hematology-oncology- journal /Full Length ArticleWilms tumor in childhood: Single centre retrospective study from the
National Institute of Oncology of Rabat and literature review
Fadoua Rais a, *, Naoual Benhmidou a, Ghizlane Rais b, Hasnaa Loughlimi a,
Fadila Kouhen a, Abdelhak Maghous a, Jihane Aarab a, Khadija Bellahammou b,
Mouna Moukinebillah d, Mohamed Khattab c, Sanaa Chala e, Sanaa Elmejjaoui a,
Tayeb Kebdani a, Hanan Elkacemi a, Noureddine Benjaafar a
a Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco
b Department of Oncology, National Institute of Oncology, Mohammed V University, Rabat, Morocco
c Department of Pediatric Hematology-Oncology, Children Hospital, Mohammed V University, Rabat, Morocco
d Department of Pediatric Radiology, Children Hospital, Mohammed V University, Rabat, Morocco
e Biostatistic Laboratory, Clinical Research and Epidemiology, Faculty of Medicine and Pharmacy of Rabat, Mohammed V Military Hospital of Instruction,
Rabat, Moroccoa r t i c l e i n f o
Article history:
Received 7 July 2016
Received in revised form
20 July 2016
Accepted 23 July 2016
Available online 2 August 2016
Keywords:
Wilms tumor
Nephroblastoma
Children
Treatment
Radiation therapy
Outcome* Corresponding author.
E-mail address: fadouarais@gmail.com (F. Rais).
Peer review under responsibility of Pediatric Hem
http://dx.doi.org/10.1016/j.phoj.2016.07.006
2468-1245/© 2016 Pediatric Hematology Oncology Ch
CC BY-NC-ND license (http://creativecommons.org/lica b s t r a c t
Background: Wilms tumor is a very common renal malignancy in children. Prognosis has been improved
dramatically during the last few decades because of multimodal treatment and successful sequential
studies. Through a retrospective study conducted in the National Institute of Oncology of Rabat, con-
cerning children with Wilms tumor treated following the International Society of Pediatric Oncology
protocol (93-01) between 2005 and 2010, we report the experience of our institute in treatment of this
malignancy. We analyze also the clinicopathologic and therapeutic aspects impacting the outcome re-
sults and compared to literature data.
Results: Fifty-two patients with Wilms tumor treated in the department of radiotherapy after receiving
chemotherapy and surgery at the department of hemato-oncology in children hospital of Rabat were
enrolled. The main characteristic was the high prevalence of locally advanced and metastatic stages
(32.6% of stage IV). With a median follow up of 54.8 months [20e79], we observed a complete response
in 32 cases (61.5%), local recurrence in only one case (1.9%), metastatic relapse in 3 cases (5.8%), both local
and metastatic recurrence in 3 cases (5.8%) and disease progression in 8 cases (15.4%). The mean duration
of overall survival was 91.2 months. The estimated 2-year and 5-year overall survival were 78.7% and
70.1% and for metastatic patients 68.8% and 62.5% respectively. At univariate analysis several parameters
were tested for survival, but only age, anaplasia, lymph node involvement, type of metastasis and
response to treatment were found to signiﬁcantly impact the overall survival. Outcome was better for
localized tumors (stage I, II and III) compared with disseminated tumors (stage IV and V) combined. Also
a better survival rate was found in the low and intermediate risk group compared to high risk, but not
statistically signiﬁcant.
Conclusion: The relatively low outcome found in this series compared to literature can be mainly
explained by the higher prevalence of metastatic disease compared to other series, but also by diagnosis
and therapeutic delay, more likely because of bad socioeconomic conditions and lack of coordination
between different operators. However, our results are nevertheless comparable to maghrebian series.
Our department has established many procedures for improving the outcome and further studies are
necessary to evaluate their efﬁciency.
© 2016 Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).atology Oncology Chapter of Indian Academy of Pediatrics.
apter of Indian Academy of Pediatrics. Production and hosting by Elsevier B.V. This is an open access article under the
enses/by-nc-nd/4.0/).
Table 1
Clinico-pathological and evolutionary features.
Clinico-pathological and
evolutionary features
Number of cases (%)
Age <5 years 29 (55.8)
>5 years 23 (44.2)
Gender Male 27 (51.9)
Female 25 (48.1)
Stage at presentation I 1 (1.9)
II 4 (7.7)
III 28 (53.9)
IV 17 (32.7)
V 2 (3.8)
Histology Low risk 2 (3.8)
Intermediate risk 35 (67.3)
High risk 15 (28.8)
Anaplasia Absent 47 (90.4)
Diffuse 4 (7.7)
Focale 1 (1.9)
Metastasis at presentation Lung only 12
Liver only 2
Lung þ Liver 4
Response to treatment Complete response 32 (61.5)
Local relapse 1 (1.9)
Metastatic relapse 3 (5.8)
Progression 8 (15.4)
Local and metastatic relapse 3 (5.8)
Total 47 (100)
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Wilms tumor or nephroblastoma is the most common renal
malignancy in children and the sixth pediatric cancer. It represents
5e10% of solid tumors and 1/3 of embryonic neoplasia [1e3]. The
last few decades have seen a dramatic change in the prognosis of
this disease. Indeed, survival rates have improved to a current ﬁve-
year overall survival rate of 90%, whereas it was only 30% with
surgery alone and only 47% with the combination radiotherapy-
surgery [4e6]. This improvement in outcome is due mainly to
multimodal treatment regimens (chemotherapy, surgery, and ra-
diation) based on sequential clinical trials.
The target of this survey is to report the epidemiological, clinical
and therapeutic features of patients treated for nephroblastoma in
the department of radiotherapy in the National Institute of
Oncology (NIO) of Rabat, Morocco with a summary review of
literature data.
2. Methods
2.1. Data collection
This is a retrospective study of 52 cases of Wilms tumor (WT)
treated in the department of radiotherapy during a period of 6
years (2005e2010), after receiving chemotherapy and surgery at
the department of hemato-oncology in children hospital of Rabat.
Analysis of clinical features, pathological ﬁndings, imaging
studies, different therapeutic modalities and outcomewas achieved
based on data from both hospitals' cancer registry of the NIO and
the children hospital of Rabat.
We got permission to access and use data from the department
head of cancer registry of Rabat. We also obtained verbal consent
from all parents or legal guardians of the patients included in this
study.
Patients were treated according to SIOP protocol 93-01 [5]. This
regimen included upfront chemotherapy followed by surgery and
then postoperative histopathological conﬁrmation of diagnosis. A
risk-based therapy (including adjuvant chemotherapy and radio-
therapy) is assigned based on results of the initial staging and
histological group disease.
Histological subtype determining histoprognosis group and
staging (I, II, III, IV or bilateral) were assessed according to the
revised SIOP Working Classiﬁcation of Renal Tumours of Childhood
(2001) [7,8].
2.2. Statistical analysis
Several factors were tested for outcome: age, gender, stage at
presentation, histological sub-type, risk group, lymph node status,
metastasis and response to treatment.
Median follow-up time was deﬁned from the date of diagnosis
to date of death or date last follow-up.
Overall survival (OS) is deﬁned as time from diagnosis to mor-
tality (for all-cause death) and patients still alive were censored at
the date of last follow-up.
Survival rates were evaluated for all patients using the Kaplan
Meier curve (SPSS 13.0) and compared by log-rank test with a
statistical signiﬁcance of 5%.
3. Results
Our series enrolled 52 patients, with a median age of 4 [3e5]
years (range from 17 months to 14 years), sex ratio (F/M) was 0.9
(Table 1). A single case of hemihypertrophywas found. However, no
other associated congenital syndrome has been noted.The median time to medical visit was 30 days [15e60], and 84%
of children consulted within three months from the beginning of
their symptoms. Clinical features were dominated by abdominal
mass in 96.2% of cases associated with pain in 30.8% of cases, he-
maturia in only 19.2% (10 cases) and fever in 13 cases (25%).
However no case of hypertension or acute abdomen symptoms was
noted.
Diagnosis was based mainly on the clinical and imaging data.
Indeed, abdominal ultrasound made in all patients and coupled to
CT scan in 82.6% of cases have shown the tumor usually as a large
renal mass, greater than 10 cm of diameter in 80.8% of cases and
well limited. They have found thrombosis of inferior vena cava
(IVC) in 10 cases (19.3%), combined to an intra-cardiac thrombosis
in 5 cases which was shown by a chest CT scan.
The two imaging modalities have allowed evoking diagnosis of
WT in 88.4% of cases. However, in 6 atypical cases (11.5%), diag-
nosis has been assessed histologically by ﬁne needle aspiration
and/or percutaneous cutting needle biopsy for the strong suspi-
cion of neuroblastoma in 5 cases and of a retroperitoneal abscess
in the sixth one. Both CT scan and chest radiography have been
used for screening lung metastases. The approach used in our
institution is the routine use of chest radiography (performed in
96% of children), supplemented by chest CT scan (performed in
36.5% of cases), only in cases of abnormal chest radiography. This
assessment revealed 18 metastatic cases (34.6%) at diagnosis (67%
in the lung only, 11% in the liver only and 22% in both lung and
liver).
Fifty children (96%) received preoperative chemotherapy ac-
cording to SIOP protocol 93-01 [5], which allowed the regression of
50% or more of the tumor mass in 43 cases (82.7%).
Surgery was performed in 96% after neoadjuvant chemotherapy,
except for 2 patients who have undergone initial surgery (because
the diagnosis of WT was missed). The surgical treatment consisted
on radical nephrectomy in all cases associated with partial contro-
lateral nephrectomy in one case of bilateral nephroblastoma, and a
metastasectomy was achieved in two cases (liver in one case and
lung in the other one). Lymph node dissection has been performed
in 15 cases (28.8%) and revealed metastatic nodes in 9 of them
(17.3%).
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to pathological assessment, which revealed 3.8% of low risk tu-
mors, 67.3% of intermediate risk and 28.8% of high risk tumors,
according to the SIOP WT 2001 staging criteria for renal tumors of
childhood [8]. We must note that rhabdoid and clear cell subtype
have not been registered in our series. Complete necrosis was seen
in 2 cases, whereas a rate of necrosis/chemotherapy inducted
changes up to 66% (witch deﬁne regressive histology) was noted in
40.4% of cases, this feature indicates low and intermediate risk
respectively [2]. Nephrogenic rests have been noted on 13 surgical
specimens (25%). Diffuse anaplasia mentioned in one case and
focal in four cases. One tumor was classiﬁed stage I, 4 tumors stage
II, 28 tumors stage III, 17 tumors stage IV and two tumors stage V
(Table 1).
Post-operative chemotherapy was administered in all patients
according to SIOP protocol 93-01 [5]. Radiotherapy was delivered
with cobalt 60 or high energy photons X in 47 cases (96.8%). The
indications retained for post-operative loco-regional radiation
therapy were stage II/III high risk group and stage III with inter-
mediate risk. Radiotherapy was delivered within an average time of
treatment of 16.6 ± 6.4 days, with a daily fraction of 1.5 Gy (for
whole abdomen irradiation) and 1.8 Gy (for ﬂank irradiation). The
median time between surgery and radiation therapy was 43 days
[33e60.5]. The ﬁelds involved were ﬂank in 32 cases (61.5%) (Doses
varied between 10.8 and 25.2 Gy), whole abdomen in 12 cases
(23%) (Doses varied between 14.4 and 16.2 Gy), with a boost to
residual nodes in 7 cases (13.5%) and to thrombosis in 6 cases
(11.5%) (Doses varied from 10.8 to 14 Gy). Also 4 lung metastatic
cases (7%) received chest radiotherapy to the lung at a dose ranging
between 10.5 and 12.6 Gray (chest radiotherapy only (N ¼ 2), one
case of combined ﬂank and chest and the last of combined whole
abdomen and chest). Chest irradiation was indicated only in cases
of residual tumors after chemotherapy and/or surgery of
metastases.Fig. 1. OverallWith amedian follow up of 54.8 months [20e79], we observed a
complete response in 32 cases (61.5%), local recurrence in only one
case (1.9%), metastatic relapse in 3 cases (5.8%), both of local and
metastatic recurrence in 3 cases (5.8%) and disease progression in 8
cases (15.4%). Five patients (9.6%) were lost of sight either before or
just after the end of radiation therapy (these patients have been
excluded from outcome results).
The mean duration of overall survival was 91.2 months. The
estimated two-year and ﬁve-year survival rates were 78.7% and
70.1% respectively (Fig. 1).
At univariate analysis several parameters were tested for sur-
vival, but only age, anaplasia, lymph node involvement, type of
metastasis and response to the treatment were found to signiﬁ-
cantly inﬂuence the overall survival (Fig. 2).
Outcome was better for localized tumors (stage I, II and III)
compared with disseminated tumors (stage IV and V) combined,
although this difference did not reach statistical signiﬁcance. Also
for histological sub-groups where was better survival in the low-
risk group compared to the intermediate one and this was better
than the high-risk group, but not statistically signiﬁcant.
At multivariate analysis, after adjustment for age, anaplasia,
lymph node involvement and delay before ﬁrst consultation none
of the studied variables was statistically associated to survival
duration.
4. Discussion
To the best of our knowledge, this study is the largest series
fromMoroccan radiotherapy-oncology centers about the outcome
of WT using SIOP protocols. The age and gender distribution were
similar to other large series, with majority (55.8%) of patients less
than 5 years old [6,9,10]. An age less than 5 years was associated
with better overall survival in our series. This joined in part the
data from the literature where better survival rate was found forsurvival.
Fig. 2. Survival curves.
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age (Fig). However, the impact of age as a prognostic factor has
been reduced currently, with the improvement of therapeutic
approaches [11].
There was a lower incidence of associated anomalies in our
study compared to the NWTS group (1.9% in our study Vs 7.3% in
NWTS group) [12]. Hemi-hypertrophy is seen in 3% of nephro-
blastomas and it is often ipsilateral to the tumor [13].
The most frequent clinical feature in our study was abdominal
mass (96,2%) compared to only 74% in United Kingdom Children's
Cancer Study Group [14]. The disparity may be due to longer time
to medical visit and then a higher number of patients presenting
with advanced disease. Therefore, in contrast to other larger
studies which have most of their patients presenting with early
stage disease [12], only one patient presented with stage I and 4
patients with stage II in our study. Other symptoms included
abdominal pain (30e40%), hematuria (12e25%) and hypertension
(25%). Our results were similar to the literature reports [15,16].
5. Diagnostic evaluation
As in literature, diagnosis was based in our series on clinical and
radiological ﬁndings [15]. But in rare cases histological evidence
(ﬁne needle aspiration and/or biopsy ﬁne needle) was required to
rule out differential diagnosis.
The ﬁrst aim of imaging is to establish the presence of a renal
tumor and to differentiate WT from other causes of abdominal
masses [15]. Abdominal US is the initial imaging study, and should
be associated with Doppler-US to detect tumor inﬁltration of the
renal vein and the presence of eventual thrombosis which wasfound in 10 cases (19.3%) in our study. Contrast-enhanced CT scan
is recommended to further evaluate the nature and extent of the
mass.
Imaging of the chest (X-rays and CT scan) is needed to
determine whether there are lung metastases and CT appears to
be more sensitive than chest radiography [17,18]. There is con-
troversy regarding the best screening modality to use for lung
metastases. In fact, it is unclear whether diagnosing these lesions
improves outcome as illustrated by the two studies of SIOP and
COG with contradictory results (no beneﬁt of routine chest CT at
diagnosis for patients with unilateral WT in SIOP study, whereas
the COG found that it improved the 5-year EFS for patients with
lung metastases detected only by CT scan and have received
more intensive therapy) [19,20]. The approach adopted in our
series was the routine use of chest radiography. A patient with
normal chest radiography is interpreted as being free of meta-
static lung disease. Thus almost all of our children beneﬁted from
a chest radiograph, whereas CT scan was performed only in 36%
of cases.
5.1. Treatment
5.1.1. Preoperative chemotherapy
Pre-operative chemotherapy is recommended to prevent intra-
operative tumor rupture, to decrease the risk of intra-operative
hemorrhage and to induce down-staging [8,21]. The SIOP re-
ported that the risk of tumor rupture decreased in sequential
studies from 33.3% to 8.0% when pre-operative chemotherapy was
done [21,22]. In our series, 96% of cases received preoperative
chemotherapy allowing regression of 50% or more of the tumor
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Tunisian WT series (only 56.2%) [1].
The third United Kingdom Children's Cancer Study Group trial
(UKW3), tested the optimal initial treatment approach for this
malignancy. Patients were randomized to immediate nephrectomy
or preoperative chemotherapy with a planned delayed nephrec-
tomy at week 6. The study showed more favorable staging and
signiﬁcant reduction in the overall burden of therapy in preoper-
ative therapy arm with the same outcomes [23]. The NWTS group
reported that extensive hemorrhage occurred less frequently
among patients with tumor thrombosis in the IVC when preop-
erative chemotherapy was administered (17.8%) [24] compared to
immediate nephrectomy (32.5%) [25]. In our study, IVC thrombosis
occurred in 10 cases (19.3%), associated with intra-cardiac
thrombosis in 5 cases, they all received preoperative chemo-
therapy without any intra-operative extensive hemorrhage case
noted.
However, the potential disadvantages of pre-operative chemo-
therapy include loss of staging information. In fact, preoperative
chemotherapy alters the tumor's histological features, distribution
of subtypes, and makes staging more difﬁcult [8].
5.2. Surgery and histological ﬁndings
Total surgical excision is the standard treatment of unilateral
WT [26]. In our series, all patients underwent radical nephrectomy,
associated to a partial contro-lateral nephrectomy in only one case
of bilateral WT. Surgery of residual metastases (excision), always
recommendedwhenever possible, was done in 2 cases, for liver and
pulmonary metastases. A review of both NWTS-4 and 5 databases
and a SIOP study suggest that sampling lymph nodes (LN) from the
hilar region is probably adequate to ensure accurate staging and
extensive LN dissection is not necessary as it appears to confer no
clinical beneﬁt [27,28]. However, the surgeon should carefully
examine all the hilar and periaortic nodes and excise any that are
suspicious [29]. Lymph node resection was achieved in 15 cases in
our series and has objectiﬁed lymph node involvement in 9 of
them.
The presence of anaplasia, has been shown as the most
important predictor of adverse outcome in children with WT in
both NWTS group and SIOP studies [30e33]. In fact, 5-year survival
of anaplastic cases in SIOP-9 does not exceed 48%. These results are
comparable to those from the NWTS study group where patients
with diffuse anaplasia accounted for more than 60% of deaths [33].
In our study, we noted only one case of diffuse anaplasia which
was resistant to ﬁrst line chemotherapy, he died during treatment
with a follow up of 8.9 months. Focal anaplasia, has been regis-
tered in 4 cases, one of them experienced complete response and
still in life with follow up of 105 months, whereas two others
patients died by progression of their disease and one was lost of
sight (Fig. 2).
5.3. Postoperative treatment
Postoperative treatment includes chemotherapy and sometimes
RT in a risk-adapted approach based on histological sub-
classiﬁcation and staging [8].
5.4. Radiotherapy (RT)
5.4.1. Localized disease
WT is one of the most radiosensitive malignancies, but the se-
quelaes caused by irradiation led to limit its use in advanced stages
(irradiation is currently indicated for approximately 20% of patients
in SIOP studies). Its main objective is to control retroperitonealdisease (tumor site and ﬁrst lymph nodes relay) in children with a
signiﬁcant risk of locoregional relapse.
RT should be given with a delay inferior to 10 days after sur-
gery. In fact the NWTS studies have shown that a delay upon or
equal to 10 days after surgery was associated with a signiﬁcantly
higher abdominal relapse rate, particularly among patients with
unfavorable histology tumors [34e36]. In the COG protocols, RT
should be given preferably by day 9 but not later than 14 after
surgery [37]. The median RT delay in our series was 43 [33e60.5]
days, and all patients have received RT after 15 days from surgery.
This delay, relatively long compared to what is recommended in
literature, is most likely related to lower OS rates in our series. For
this reason our department has adopted a new program of pri-
ority of starting RT treatment according to the degree of tumor
emergency and WT is among the priority number II (with the
others childhood malignancies) which should be treated by a
delay less than 14 days. Postoperative RT was administered to our
patients according to SIOP 93-01 protocol. The recommended
dose of RT is 15 Gy in low- and intermediate-risk group with
stage III disease and 30 Gy in high-risk patients [38]. In NWTS
studies (1e4), no RT dose response has been shown. Therefore it
was decided to treat all abdominal disease with 10 Gy [35,36,39].
Similar dose is used in the COG protocols for most indications
(except for stage III diffuse anaplasia and stages I to III Rhabdoid
tumor of the kidney, where a higher dose of 19.8 Gy is recom-
mended) [40,41].
5.4.2. Metastatic disease
Negative impact on survival of omitting RT in metastatic sites,
has been shown in an analysis of the effect of whole-lung RT on EFS
and OS from UKW3 [42,43]. However, the morbidity associated
with RT, and the risk of secondary malignancies have again been
conﬁrmed in an analysis of more than 8000 WT pooled from Eu-
ropean and North American studies [42,44].
The metastatic response-adapted approach by omission of RT
in the SIOP WT 2001 trial aimed to address this balance of risk.
The results showed that survival correlates with completeness of
lung node response. Comparable results have been found by the
recently completed COG AREN0533 study [42,45]. Results from
the complete response group (favorable histology) who did not
receive whole-lung RT, have just been presented in the 2015
ASCO Annual Meeting. They have shown a slight decrease of EFS
non statistically signiﬁcant, whereas OS remained excellent
(95%). These ﬁndings suggest that omission of lung RT may
provide an acceptable treatment approach for this patient sub-
group [46]. So clinicians should balance the beneﬁt of avoidance
of lung RT against the possibility of a modest increase in relapse
risk [46].
In our series we noted 4 lung metastatic cases (7%) which
received RT to the whole-lung at a dose ranging between 10.5 and
12.6 Gray, two of them are still alive with complete response
(follow up of 56 and 60 months respectively), while the two
remaining cases died by progression of their disease.
5.5. Adjuvant chemotherapy
In our series, all patients have received adjuvant chemotherapy
according to SIOP protocol 93-01 [5]. Currently, the most important
question regarding adjuvant chemotherapy in WT is the possibility
of omission of doxorubicin from stage IIeIII intermediate-risk WT.
That has been studied in SIOP 2001 trial and concluded that
doxorubicin could be safely removed when histological response to
preoperative chemotherapy is incorporated into the risk stratiﬁ-
cation. This approach will spare many patients the potential
adverse effects of doxorubicin exposure [45,47].
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The overall survival rate relatively low in this series compared to
literature data can be explained by the higher prevalence of met-
astatic disease compared to that reported in large series (10e15% Vs
32.6% in our series). This high rate is probably related to a referral
bias, in fact patients who are referred to our department are more
advanced stages and/or at high-risk of recurrence than standard
series and they are potential candidates to receive adjuvant RT. OS
of these metastatic patients does not exceed 68.8% at 2 years and
62.5% at 5 years (Fig. 2).
Our results are nevertheless comparable to maghrebian series.
Indeed in a Tunisian retrospective study enrolling 35 WTs over a
period of 8 years (with a minority of patients from stage IV), the 5-
years OS was only 80% [1].
6. Conclusion
Patients with childhood WT are still treated with diagnosis and
therapeutic delay in our setting, more likely because of bad socio-
economic conditions and lack of coordination between different
operators. These factors negatively impacted the prognosis in our
series. Our department has established many procedures for
improving the outcome and further studies are necessary to eval-
uate their efﬁciency. Better coordination between the various op-
erators including onco-pediatricians, surgeons, pathologists and
radiotherapists remains essential for better management of this
tumor. The focus of ongoing studies is still continuing the
improvement of outcome, particularly for high-risk group patient
and minimization of long-term treatment burden in this
malignancy.
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